Gateway Investment Advisers LLC Acquires 5,726 Shares of Edwards Lifesciences Co. (NYSE:EW)

Gateway Investment Advisers LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 97.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,581 shares of the medical research company's stock after buying an additional 5,726 shares during the quarter. Gateway Investment Advisers LLC's holdings in Edwards Lifesciences were worth $857,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FSA Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter worth about $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences in the third quarter worth approximately $32,000. Avior Wealth Management LLC raised its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Peoples Bank KS purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $40,000. Finally, Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $46,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company's stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 in the last three months. 1.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on EW shares. The Goldman Sachs Group increased their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, December 5th. Morgan Stanley reissued an "equal weight" rating and set a $70.00 price objective on shares of Edwards Lifesciences in a report on Friday, October 11th. Evercore ISI cut their target price on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a research note on Tuesday, October 1st. Piper Sandler lowered their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Finally, Royal Bank of Canada lifted their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $78.48.

Edwards Lifesciences Stock Down 0.1 %

EW traded down $0.09 on Friday, hitting $69.77. The company had a trading volume of 5,031,232 shares, compared to its average volume of 4,364,863. The stock has a fifty day simple moving average of $72.06 and a 200-day simple moving average of $71.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $41.15 billion, a P/E ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts' consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.